Drug Safety Alert: IPC Flags Adverse Reactions to Metronidazole, Luliconazole, Dalteparin, Gliclazide, and Tramadol Susmita Roy28 March 2025 6:00 PM ISTNew Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of March, has revealed adverse drug...
Eris Lifscience Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Dr. Divya Colin29 Sept 2024 6:00 PM ISTNew Delhi: Reviewing the bioequivalence (BE) study report of the fixed-dose combination (FDC) antidiabetic drug Dapagliflozin Propanediol Monohydrate...
Indian Review Revisits Legacy Effect of Gliclazide in Diabetes Management Dr. Kamal Kant Kohli21 Sept 2023 11:15 AM ISTTaking strong note of the effective glycemic control and vascular benefits shown by early intensive treatment with Gliclazide MR (modified release) in...
ESC 2023 Reaffirms CV Safety of Sulphonylureas Agents Dr. Prem Aggarwal30 Aug 2023 11:30 AM ISTThe European Society of Cardiology (ESC) has released new guidelines for managing cardiovascular disease among patients with diabetes, simplifying...
Initiate Phase III CT: CDSCO panel tells Eris Lifesciences for FDC Gliclazide, Sitagliptin Dr. Divya Colin28 Feb 2023 5:45 PM ISTNew Delhi: Based on the bioequivalence (BE) report submitted by the drug major Eris Lifesciences, the Subject Expert Committee (SEC) functional under...
Among elderly, gliclazide tied to severe hypoglycemia risk compared to glimepiride Dr. Shravani Dali14 Jun 2022 10:15 AM ISTIn older adults, gliclazide modified release (MR) was associated with greater severe hypoglycemia (SH) risk compared with glimepiride according to a...
Health Bulletin 19/February/2022 Roshni Dhar19 Feb 2022 5:28 PM ISTHere are Top Health stories for the dayOnline courses to doctors even if mandated by Medical Council should be taxed under GST: AAR Delhi: Medical...
Serdia Pharma bags CDSCO approval for anti-diabetic FDC of extended-release Gliclazide 60mg plus Metformin 1000mg tablet Roshni Dhar19 Feb 2022 8:15 AM ISTIn a significant development, Serdia Pharmaceuticals (India) Pvt. Ltd. has got approval from the Central Drugs Standard Control Organization (CDSCO)...
Serdia Pharma gets CDSCO nod for anti-diabetic FDC of extended-release Gliclazide 60mg plus Metformin 1000mg tablet Susmita Roy18 Feb 2022 1:34 PM ISTNew Delhi: In a significant development, Serdia® Pharmaceuticals (India) Pvt. Ltd. has got approval from the Central Drugs Standard Control...
NPPA Fixes Retail Price Of 41 Formulations; Details Medical Dialogues Team19 March 2021 1:44 PM ISTNew Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India,...
Gliclazide modified release better second-line treatment than sitagliptin for type 2 diabetes patients on Metformin- Study Hina Zahid9 Oct 2020 9:44 AM ISTUK: Gliclazide modified release (MR) is more effective in reducing blood sugar levels than sitagliptin in type 2 diabetes (T2D) patients already...
Indian Sub-analysis of DIA-RAMADAN Study: Gliclazide XR 60 mg found safe, effective in blood sugar management during Ramadan Meghna A Singhania23 Sept 2020 10:39 AM ISTNew Delhi: Gliclazide XR 60 mg given to type 2 diabetes (T2D) patients during Ramadan fast helped in a significant reduction of blood sugar levels...
